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The Cost of Doing Invasive Business*Robert D. Saﬁan, MDSEE PAGE 1229S troke is the third most common cause of deathand the most common cause of disability inthe United States, so therapies designed to
prevent stroke are worthy of study. The road to
stroke prevention crosses paths with many diseases,
so prevention depends on identifying conditions
associated with stroke, including atherosclerosis,
hypertension, intracranial aneurysms, atrial ﬁbrilla-
tion, vasculitis, and others. Because many condi-
tions coexist in the same patient, a single strategy
may not be sufﬁcient to prevent stroke. Atheroscle-
rosis of the internal carotid artery (ICA) accounts
for 12% of strokes, and contemporary approaches to
stroke prevention include carotid endarterectomy
(CEA), carotid artery stenting (CAS), and medical
therapy. Because stroke is often due to embolization
rather than progressive stenosis leading to occlu-
sion, the mechanisms for stroke prevention include
a combination of stenosis reduction, lesion passiv-
ation, and plaque stabilization. A practical therapeu-
tic dilemma is that stroke can occur despite these
therapeutic strategies and may occur as an inadver-
tent complication of treatment. Accordingly, the
beneﬁts of the therapy must be weighed against
the risks; the CREST-2 trial (Carotid Revasculariza-
tion and Medical Management for Asymptomatic
Carotid Stenosis Trial) will answer some unresolved
issues about the risks and beneﬁts of carotid
revascularization (CEA, CAS) and optimal medical
therapy (hypertension and glycemic control, statins,
antiplatelet agents), but the results are not expected
for at least 5 years (1).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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of medical therapy and carotid revascularization,
there is tremendous focus on ways to optimize CAS
technique. In this issue of JACC: Cardiovascular
Interventions, Schofer et al. (2) report their ﬁndings in
a prospective observational study of 30 patients who
underwent CAS with the CGuard Carotid Embolic
Protective Stent System (InspireMD, Boston, Massa-
chusetts) as part of the CGuard CARENET (Carotid
Embolic Protection Using MicroNET) trial. Unlike
other carotid stents, the CGuard is a self-expanding
nitinol stent combined with a polyethylene tetraph-
thalate mesh, designed to trap atherosclerotic debris,
stabilize the plaque surface, and prevent stroke. The
CGuard is available as 6 to 10  20 to 60-mm stents
(diameter  length), and when fully expanded, the
pore size is 150 to 180 mm. In principle, the CGuard
is similar to the MGuard (balloon-expandable stent
with similar mesh; InspireMD), which was evaluated
in patients with ST-segment elevation myocardial
infarction (MI) in the MASTER (Safety and Efﬁcacy
Study of MGuard Stent After a Heart Attack) trial (3).
Inclusion criteria were symptomatic ICA stenosis
>50% (10 patients) and asymptomatic ICA stenosis
>80% (20 patients); patients were excluded for lesion
length >30 mm, circumferential calciﬁcation, stroke
within 30 days, MI within 3 days, and known atrial
ﬁbrillation. All patients received embolic protection
devices (EPDs; 29 distal EPDs and 1 proximal EPD).
The primary endpoints were procedure success
(deployment and retrieval of CGuard) and the number
of new ipsilateral acute ischemic lesions (AIL) by
brain diffusion-weighted magnetic resonance imag-
ing (DW-MRI) at 48 h and 30 days after CAS; MRIs
were performed in 28 of 30 patients before CAS, 27 of
30 patients at 48 h, and 26 of 30 patients at 30 days.
Secondary endpoints were major adverse events
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1236(including death, MI, and stroke) at 30 days, and ﬂow
in the external carotid artery after stent deployment.
The principal ﬁndings of CARENET are 100% proce-
dural success (no injury to the external carotid
artery); new ipsilateral AIL in 37% at 48 h (resolved
by 30 days in all but 1 patient) and 3.8% at 30 days;
and major adverse cardiac and cerebrovascular
events of 0% at 30 days.
The CARENET study has several limitations (small
number of patients, unspeciﬁed statin and anti-
platelet therapy, lack of uniformity in EPDs, no
late follow-up), but nevertheless provides important
insight into cerebral embolization after endovascular
procedures in general, and CAS in particular. The
DW-MRI ﬁndings suggest that cerebral embolization
is quite common, despite best efforts to prevent it: at
48 h, new ipsilateral, contralateral, and bilateral AIL
were identiﬁed in 37%, 22%, and 46% of patients.
Although the incidence of new AIL at 30 days was
only 3.8%, another study reported that 20% of strokes
occur after discharge and within 30 days (4). These
ﬁndings suggest that atheroembolization to the brain
may occur from multiple sources, including the aortic
arch, the great vessels, and the ICA stenosis; although
most episodes occur early, delayed stroke is possible.
The clinical signiﬁcance of asymptomatic ischemic
lesions by MRI is unclear, although some studies
suggest a relationship between spontaneous asymp-
tomatic ischemic lesions and cognitive dysfunction
(5). Other studies reported new AIL by DW-MRI
after CAS and CEA (6), but the relationship between
iatrogenic asymptomatic AILs and late cognitive
dysfunction has not been delineated; many AILs
are reversible within 30 days (2). From a technical
perspective, potential strategies for preventing cere-
bral atheroembolization from the arch and great
vessels include deﬂecting devices such as Embrella
(Edwards Lifesciences, Irvine, California) and dual-
ﬁlter devices such as the Sentinel Cerebral Protec-
tion System (Claret Medical, Santa Rosa, California).
The Sentinel system is currently under investiga-
tion in a randomized trial of cerebral protection
in patients undergoing transcatheter aortic valve
implantation, relying on DW-MRI, stroke, andcognitive dysfunction (by neuropsychiatric testing) as
endpoints.
In addition to the risks of atheroembolization
from the arch and great vessels, there are many
potential causes of embolization during CAS:
manipulation of interventional hardware in the
common carotid artery; crossing the ICA stenosis
with the guidewire, balloons, and stents; passage
and retrieval of EPDs; plaque protrusion through the
stent struts; platelet deposition on the stent struts;
and translocation of lipid core plaque. Even though
a number of reports suggest fewer DW-MRI AILs
when using proximal versus distal EPDs, and for
hybrid and closed-cell stents versus open-cell designs,
experts do not agree on their superiority (6–10).
To me, one of the most compelling features of
the CGuard is the potential added layer of security
against distal embolization by stabilizing the lesion
surface. Optical coherence tomography demon-
strates a high incidence of plaque protrusion after
CAS, which may partially explain early and late
stroke and new AILs by DW-MRI (11). Most plaque
protrusion occurs after stent deployment and ﬁnal
angioplasty, so a simple solution may be to avoid
ﬁnal balloon inﬂations unless clearly needed for
lumen enlargement. Using near-infrared spectros-
copy, we reported translocation of lipid core plaque
after CAS (12). Together, these observations suggest
that plaque features and behavior are relevant
to CAS outcomes and may be favorably affected
by devices such as CGuard. Because prior experience
with nonporous covered stent designs was not favor-
able, the pore size of the CGuard is quite large, and the
incidence of late restenosis and stroke is presently
unknown, further study is clearly needed. For the
time being, it appears that cerebral atheroemboliza-
tion is part of the cost of doing business during CAS
and other invasive procedures.
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